Vasopressin-receptor antagonists - PubMed (original) (raw)
Review
Vasopressin-receptor antagonists
Ewout J Hoorn et al. Future Cardiol. 2010 Jul.
Abstract
Despite a crucial role in body fluid homeostasis, elevated vasopressin levels can also be pathological in conditions such as congestive heart failure, liver cirrhosis and the syndrome of inappropriate antidiuretic hormone secretion. The result of elevated vasopressin is renal water retention and hyponatremia, a low serum sodium concentration. Hyponatremia is associated with excess morbidity and mortality. Nonpeptide vasopressin-receptor antagonists represent a new drug class of small molecules that competitively inhibit one or more of the vasopressin receptors. There are three vasopressin receptors in humans, including V1a, V1b and V2. Selective V2- and combined V1a/V2-receptor antagonists have been developed for the treatment of hyponatremia resulting from congestive heart failure, liver cirrhosis and the syndrome of inappropriate antidiuretic hormone secretion. Two nonpeptide vasopressin-receptor antagonists, conivaptan and tolvaptan, have recently been approved by American and European drug authorities for clinical use. This article aims to provide a succinct and clinical update on nonpeptide vasopressin-receptor antagonists, including their mechanism of action, performance in randomized clinical trials and current clinical status.
Similar articles
- Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
Ali F, Raufi MA, Washington B, Ghali JK. Ali F, et al. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. doi: 10.1111/j.1527-3466.2007.00019.x. Cardiovasc Drug Rev. 2007. PMID: 17919259 Review. - Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Palm C, Pistrosch F, Herbrig K, Gross P. Palm C, et al. Am J Med. 2006 Jul;119(7 Suppl 1):S87-92. doi: 10.1016/j.amjmed.2006.05.014. Am J Med. 2006. PMID: 16843091 Review. - The use of vasopressin receptor antagonists in hyponatremia.
Khanna A, Menon MC. Khanna A, et al. Curr Opin Investig Drugs. 2010 Sep;11(9):1007-14. Curr Opin Investig Drugs. 2010. PMID: 20730695 Review. - Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
Ghali JK, Zmily HD, Farah JO, Daifallah S. Ghali JK, et al. IDrugs. 2010 Nov;13(11):782-92. IDrugs. 2010. PMID: 21046526 Review.
Cited by
- Diagnosis and Treatment of Hyponatremia: Compilation of the Guidelines.
Hoorn EJ, Zietse R. Hoorn EJ, et al. J Am Soc Nephrol. 2017 May;28(5):1340-1349. doi: 10.1681/ASN.2016101139. Epub 2017 Feb 7. J Am Soc Nephrol. 2017. PMID: 28174217 Free PMC article. Review. - Tolvaptan.
Rangarajan B, Binoy V, Hingmire SS, Noronha V. Rangarajan B, et al. South Asian J Cancer. 2014 Jul;3(3):182-4. doi: 10.4103/2278-330X.136811. South Asian J Cancer. 2014. PMID: 25136528 Free PMC article. - Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects.
Shoaf SE, Mallikaarjun S, Bricmont P. Shoaf SE, et al. Eur J Clin Pharmacol. 2012 Feb;68(2):207-11. doi: 10.1007/s00228-011-1106-4. Epub 2011 Aug 19. Eur J Clin Pharmacol. 2012. PMID: 21853290 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources